# Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

> **NCT03679611** · PHASE4 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 120 (actual)

## Conditions studied

- Obstructive Sleep Apnea

## Interventions

- **DRUG:** Sugammadex Sodium
- **DRUG:** Neostigmine

## Key facts

- **NCT ID:** NCT03679611
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-14
- **Primary completion:** 2021-10-26
- **Final completion:** 2021-10-26
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03679611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03679611, "Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03679611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*